Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 437 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: reference group Clear all
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 4, 2026, 2:57 PM EDT
Completed No phase listed Observational

Replication of the CARMELINA Diabetes Trial in Healthcare Claims

NCT03936036
View directory record Official record
Conditions
Diabetes
Interventions
Linagliptin, Sulfonylurea
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
101,830 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 4, 2026, 2:57 PM EDT
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients

NCT03332147
View directory record Official record
Conditions
Vital Sign Monitoring
Interventions
Investigational Group, reference group-Earlysense system
Device
Lead sponsor
Darma Inc.
Industry
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 4, 2026, 2:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Infant Formula and Toddler Drink Feeding Intervention

NCT04495738
View directory record Official record
Conditions
Respiratory Infections in Children
Interventions
Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Supplemental Formula for HM Group, Toddler Drink for HM group
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
27
States / cities
Dothan, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 4, 2026, 2:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Virtual Reality During Procedures in Pediatric Patients

NCT03686176
View directory record Official record
Conditions
Virtual Reality, Pediatrics
Interventions
Virtual Reality
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 26 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth and Tolerance of Young Infants Fed Infant Formula

NCT04105686
View directory record Official record
Conditions
Growth and Tolerance
Interventions
Control Infant Formula, Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System

NCT02041286
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi Contour Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 4, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

NCT05635357
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Exemestane/Letrozole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
16,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 3 Interventional

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

NCT06261957
View directory record Official record
Conditions
Asthma
Interventions
Salbutamol HFA-134a, Salbutamol HFA-152a
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
37
States / cities
North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 2:57 PM EDT
Enrolling by invitation Not applicable Interventional

CPNF Intervention Development and Testing

NCT07036198
View directory record Official record
Conditions
Alcohol Use
Interventions
Customizable personalized normative feedback (CPNF), Personalized normative feedback (PNF), Attention-Matched Control (AMC)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 24 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 4, 2026, 2:57 PM EDT
Not listed Not applicable Interventional

Home-Based Physical Activity Intervention for Taxane-Induced CIPN

NCT04621721
View directory record Official record
Conditions
Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness
Interventions
Gait/balance & resistive exercise
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

NCT03973775
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Cream 5%
Drug
Lead sponsor
Saptalis Pharmaceuticals LLC
Industry
Eligibility
2 Months to 65 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Dinuba, California • Long Beach, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 4, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouth Rinses and Flossing

NCT05600231
View directory record Official record
Conditions
Healthy
Interventions
LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 4, 2026, 2:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison Studies Comparing Hemodynamic Parameters Provided by the Caretaker Against Respective Gold Standard References

NCT05035719
View directory record Official record
Conditions
Cardiac Output, Low
Interventions
non-invasive cardiac output monitor
Device
Lead sponsor
CareTaker Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 4, 2026, 2:57 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure

NCT07775495
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Not listed
Lead sponsor
Ecotera Health LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
51
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 2:57 PM EDT
Completed No phase listed Observational

Replication of the P04334 Asthma Trial in Healthcare Claims Data

NCT04892758
View directory record Official record
Conditions
Asthma
Interventions
Formoterol fumarate 10 mcg, Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 120 Years
Enrollment
10,288 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions
Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 4, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 4, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

NCT01769677
View directory record Official record
Conditions
Pain
Interventions
90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 4, 2026, 2:57 PM EDT